[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637235":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":39,"locations":48,"responsibleParty":67,"collaborators":69,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":25,"enrollmentInfo":82,"targetDuration":25,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":51,"whyStopped":25,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Pleryon Therapeutics (Hangzhou) Limited","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1","EXPERIMENTAL","Part 1 Participants",[13],"Drug: Part 1: ABR2 single dose in one eye",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 2","Part 2 Participants",[18],"Drug: Part 2 ABR2 At least twice a day for 28 days",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Part 2 ABR2 At least twice a day for 28 days","Use ABR2 at least BID, up to QID for 28 days",[15],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Part 1: ABR2 single dose in one eye","Receive a single dose in one eye only",[9],[31,35],{"name":32,"affiliation":33,"role":34},"Charis Lau, PharmD, OD","Pleryon Therapeutics","STUDY_CHAIR",{"name":36,"affiliation":37,"role":38},"Jill Woods, MSc, MCOptom","Centre for Ocular Research & Education, University of Waterloo","PRINCIPAL_INVESTIGATOR",[40,45],{"name":41,"role":42,"phone":43,"phoneExt":25,"email":44},"CORE Studies","CONTACT","519-888-4742","corestudies@uwaterloo.ca",{"name":46,"role":42,"phone":43,"phoneExt":25,"email":47},"Ulli Stahl, PhD","ustahl@uwaterloo.ca",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Centre for Ocular Research & Education, School of Optometry & Vision Science, University of Waterloo","RECRUITING","Waterloo","Ontario","N2L 3G1","Canada","CA",{"type":58,"coordinates":59},"Point",[60,61],-80.51639,43.4668,{"lat":61,"lon":60},[64,65,66],{"name":41,"role":42,"phone":43,"phoneExt":25,"email":44},{"name":46,"role":42,"phone":43,"phoneExt":25,"email":47},{"name":36,"role":38,"phone":25,"phoneExt":25,"email":25},{"type":68,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[70],{"name":71,"class":72},"University of Waterloo School of Optometry and Vision Science","UNKNOWN","100637235","evaluation-of-a-novel-ocular-lubricating-eye-drop-100637235",false,"NCT07593404","Evaluation of a Novel Ocular Lubricating Eye Drop","DRAGON","Inclusion Criteria:\n\n1. Are at least 18 years of age and have capacity to volunteer\n2. Are able to read (Part 2 only);\n3. Have signed an information and consent letter;\n4. Are willing to follow instructions and maintain the appointment schedule;\n5. Are willing to refrain from contact lens wear throughout the study period;\n6. Have a best corrected visual acuity of +0.20 LogMAR or better in each eye;\n7. Have an OSDI score ≥13 AND at least one of the following signs in at least one eye: Non-invasive tear film break-up time (NITBUT) \\\u003C 10 sec, AND\u002FOR ocular surface staining (\\> 5 corneal spots, and\u002F or \\> 9 conjunctival spots)\n\nExclusion Criteria:\n\n1. Participation in another ocular clinical research study or pharmaceutical clinical study within the past 14 days;\n2. Have a known active ocular disease and\u002F or infection with the exception of dry eye disease;\n3. Have any slit lamp findings that would contraindicate use of the study product;\n4. Have a systemic condition that would contraindicate use of the study product;\n5. Are using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable;\n6. Have undergone refractive error surgery or intraocular surgery within the last 12 months;\n7. Have any known sensitivity or allergy to the diagnostic sodium fluorescein or to any ingredients in the study product;\n8. Are using ocular lubricating eye drops more than twice per day on a typical day over the past month (Part 2 only);\n9. Are an employee of the Centre for Ocular Research \\& Education directly involved in this study","ALL","18 Years",{"count":83,"type":84},40,"ESTIMATED","INTERVENTIONAL",[87],"NA","The objective of this 2-part study is to assess the safety and tolerability of the new ocular lubricating drop ABR2 during short-term use in subjects for the temporary relief of ocular discomfort due to dryness of the eye.\n\nIn Part 1, participant will receive 1 drop of ABR2 in one eye and through assessments over a 1-hour period.\n\nIn Part 2, participant will use 1 drop of ABR2 at least two times a day for 28-day period (may use up to 4 times a day as needed) This is a single arm, open label study with no placebo or comparative arm.",[90],"Dry Eye Syndrome (DES)",[92,93,94],"dry eye syndrome","ophthalmic solution","lubrication","2026-05-15",{"date":97,"type":98},"2026-05-19","ACTUAL",{"date":100,"type":84},"2026-05",{"date":102,"type":84},"2027-05",{"name":5,"class":6},1]